BayesCare Precision Medicine / PGx Dosing
Checking PGx service Back to modules
Precision Medicine / Pharmacogenomics

Genotype- and population-aware dosing
for three high-actionability drugs.

CPIC-guideline dosing for tacrolimus (CYP3A5), carbamazepine (HLA-B*15:02), and phenytoin (CYP2C9) -- with a population-frequency prior when a patient's genotype isn't known yet, corroborated live against India's GenomeIndia database (GI-DB, 9,768 individuals, IGIB).

Decision-support only. Population-prior estimates apply only when a genotype/test result is unknown and are not a diagnosis. Confirmatory genetic testing is recommended where feasible, especially before acting on the carbamazepine/HLA-B*15:02 guidance. Verify against current CPIC/PharmGKB guidance and use clinical pharmacist/physician judgment before any prescribing decision.

Tacrolimus starting dose -- CYP3A5

CPIC: expressers need ~1.5-2x the non-expresser starting dose.

Carbamazepine safety screen -- HLA-B*15:02

CPIC/FDA: test before starting in patients of Asian (incl. Indian) ancestry.

Phenytoin dose adjustment -- CYP2C9

CPIC: PM ≥50% reduction, IM ≥25% reduction of starting dose.

Extended CPIC gene–drug assessments

The additional pathways are discovered from the live backend catalogue. Test results must be confirmed; untested does not mean negative.

Loading supported gene–drug pathways…

Research decision support only. This form does not call genotypes from raw variants, validate a genetic test, or replace current CPIC guidance, lab interpretation, TDM or professional prescribing judgment.